Business Context and Reporting Period
TASER International, Inc. (now Axon Enterprise, Inc.) filed this Form 10-Q for the quarter ended March 31, 2016. The company operated through two reportable segments: TASER Weapons, comprising conducted electrical weapons, accessories and related services; and Axon, comprising cameras, Evidence.com and digital evidence-management solutions.
Financial Performance and Position
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Net sales | $55.5 million | $44.8 million | Up 24.1% |
| Gross margin | $36.9 million; 66.5% | $29.9 million; 66.7% | Gross profit up 23.5%; margin broadly stable |
| Operating income | $5.1 million; 9.3% margin | $10.7 million; 24.0% margin | Down 52.1% |
| Net income | $3.5 million; 6.2% margin | $7.2 million; 16.1% margin | Down 51.9% |
| Diluted EPS | $0.06 | $0.13 | Down $0.07 |
| Operating cash flow | $7.1 million | $13.0 million | Down $5.9 million |
- TASER Weapons revenue increased 19.5% to $45.8 million. Axon revenue increased 51.0% to $9.7 million, driven primarily by Evidence.com revenue, which rose 139.2% to $4.6 million.
- International revenue increased 41.0% to $13.1 million and represented 23.5% of sales, compared with 20.7% in the prior-year quarter.
- Bookings for Axon products and Evidence.com, net of reversals, increased 126.9% to $52.1 million. Future bookings may be subject to municipal appropriations or contract-cancellation provisions.
- Operating expense growth substantially exceeded revenue growth: SG&A increased 70.5% to $24.8 million and research and development increased 52.0% to $6.9 million. The increases reflected hiring, sales and marketing investment, international expansion, Axon development and infrastructure spending.
- Axon gross margin improved to 53.1% from 40.6%, while TASER Weapons gross margin declined to 69.3% from 71.1%. Consolidated gross margin was essentially unchanged.
- Cash, cash equivalents and investments totaled $114.1 million at March 31, 2016, including $53.4 million of cash and cash equivalents. Total assets were $237.1 million and total liabilities were $83.9 million.
- Deferred revenue increased to $55.4 million from $51.0 million at December 31, 2015, supporting the recurring and multi-year nature of certain warranty, hardware and Axon services arrangements.
- The company had approximately $0.1 million of notes payable and capital lease obligations, no revolver borrowings, and approximately $7.0 million of available revolver capacity after $3.0 million of outstanding letters of credit.
Material Changes Versus Comparable Period
- Revenue growth was led by TASER X26P and X2 weapons, cartridge sales, international orders and recurring Evidence.com services. Axon camera revenue was temporarily affected by the transition to the Axon Body 2, which created a backlog while customers shifted orders from older camera models.
- Profitability declined despite higher sales because SG&A and R&D expanded significantly. Management emphasized continued investment to support Axon growth, product development and scalable infrastructure.
- Operating cash flow declined because of lower earnings and working-capital uses, including increases in receivables, inventory and prepaid assets. Inventory rose to $20.2 million from $15.8 million at year-end.
- The company repurchased approximately 475,000 shares for $9.0 million during the quarter under a newly authorized $50.0 million program. A subsequent event disclosed an additional 1.0 million shares repurchased for approximately $18.7 million through May 6, 2016.
- The company recorded approximately $0.7 million of out-of-period expenses in Q1 2016 that should have been recorded in Q4 2015. Management concluded the adjustment was not material to either period, but disclosed related control deficiencies.
Guidance, Outlook, Risks and Unusual Items
- Management expected higher recognized revenue from Axon Body 2 cameras and accessories during the remainder of 2016 as the camera backlog was fulfilled. It also expected continued growth in on-officer cameras and Evidence.com.
- Management estimated a 2016 effective tax rate of approximately 33.8% before discrete adjustments, compared with a 34.2% effective rate in Q1. Tax outcomes remain sensitive to international income, tax-credit utilization and uncertain tax positions.
- Management believed available cash, investments, operating cash flow and the revolving credit facility would fund operations and strategic initiatives through 2016 and the foreseeable future.
- The company maintained approximately $3.6 million of unrecognized tax benefits and a valuation allowance related to certain tax assets. The filing states that approximately $48.0 million of future U.S. pre-tax book income would be needed to realize the net deferred tax assets for which a benefit was recorded.
- Nine product-liability lawsuits remained active, involving alleged wrongful death or personal injury associated with TASER CEWs. Management did not believe the matters were reasonably likely to materially affect results, but acknowledged that litigation outcomes are inherently uncertain and insurance may not cover all losses.
- The company disclosed a patent and trademark lawsuit against Phazzer, litigation brought by Digital Ally alleging patent infringement and other claims, and a subsequent arbitration claim by a former French distributor involving approximately $0.6 million.
- Outstanding off-balance-sheet support arrangements included approximately $3.0 million of letters of credit and $4.7 million of surety bonds.
- Disclosure controls and procedures were deemed ineffective as of March 31, 2016 because deficiencies in liability identification and recording caused the out-of-period adjustments. Management expected remediation before year-end 2016.
- Key operating risks included government budget and appropriation constraints, product defects and warranty costs, data-security breaches or Evidence.com outages, competition, supply-chain capacity, foreign-exchange fluctuations, litigation, intellectual-property disputes and execution risk associated with rapid Axon growth.
Most Important Facts for Investors to Verify
- Whether the Axon Body 2 backlog was fulfilled as expected and translated into recognized camera revenue during the remainder of 2016.
- Whether Axon bookings convert into revenue despite appropriation clauses and other cancellation rights in government contracts.
- Whether elevated SG&A and R&D investments produce sustained Axon growth and improved segment profitability.
- The status and potential financial exposure of product-liability, Digital Ally, Phazzer and distributor arbitration matters.
- Progress in remediating the ineffective disclosure controls and whether additional accounting errors are identified.
- Inventory levels, warranty reserves and any further valuation adjustments associated with new products.
- Cash deployment under the $50.0 million repurchase authorization and its effect on liquidity and share count.
- Realization of deferred tax assets and resolution of the approximately $3.6 million of unrecognized tax benefits.